Trial · NCT03068455
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Recurrence-free Survival (RFS) - All Randomized Participants | From randomization to Primary Completion Date (up to approximately 3 years) | All randomized participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma | Months | MEDIAN |
| PRIMARY | Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level < 1% | From randomization to Primary Completion Date (up to approximately 3 years) | All randomized participants with PD-L1 expression level \< 1% and with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma. PD-L1 expression levels based on Interactive Response Technology (IRT) | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) - All Randomized Participants | From randomization to date of death (up to approximately 45 months) | All randomized participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) - All Randomized Participants With PD-L1 Expression Level < 1% | From randomization to date of death (up to approximately 45 months) | All randomized participants with PD-L1 expression level \< 1% and with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma | Months | MEDIAN |
| SECONDARY | Recurrence-free Survival (RFS) by Baseline Tumor PD-L1 Expression | From randomization to Study Completion Date (up to approximately 45 months) | All randomized participants with variable PD-L1 expression levels (see data table for details). PD-L1 expression levels based on clinical database. | Months | MEDIAN |
| SECONDARY | Time to Next-Line Therapies - All Randomized Participants | From randomization to start of next therapy or second next therapy (up to approximately 45 months) | All randomized participants | Months | MEDIAN |
| SECONDARY | Time to Next-Line Therapies - All Randomized Participants With PD-L1 Expression Level < 1% | From randomization to start of next therapy or second next therapy (up to approximately 45 months) | All randomized participants with PD-L1 expression level \< 1% | Months | MEDIAN |
| SECONDARY | Time From Next Therapy to Second Next Therapy - All Randomized Participants | From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months) | All randomized participants who received first and second next systemic therapy | Months | MEDIAN |
| SECONDARY | Time From Next Therapy to Second Next Therapy - All Randomized Participants With PD-L1 Expression Level < 1% | From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months) | All randomized participants with PD-L1 expression level \< 1% who received first and second next therapy | Months | MEDIAN |
| SECONDARY | Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants | From randomization to progression event (up to approximately 45 months) | All randomized participants | Months | MEDIAN |
| SECONDARY | Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants With PD-L1 Expression Level < 1% | From randomization to progression event (up to approximately 45 months) | All randomized participants with PD-L1 expression level \< 1%. | Months | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03068455/outcomes